The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Sunovion Pharmaceuticals Inc. is initiating a withdrawal of all undispensed Kynmobi® (apomorphine HCl) sublingual film and Lonhala® Magnair® (glycopyrralate) Inhalation Solution from the U.S. marketplace, due to limited utilization. This action will commence as of June 30, 2023. The deadline for this withdrawal will be September 30, 2023. The withdrawal is being conducted with the knowledge of the U.S. FDA and impacts all lots of KYNMOBI and LONHALA MAGNAIR.

NDC	Description of Products Subject to this Withdrawal
63402-0010-30	KYNMOBI 10MG x 30
63402-0015-30	KYNMOBI 15MG x 30
63402-0020-30	KYNMOBI 20MG x 30
63402-0025-30	KYNMOBI 25MG x 30
63402-0030-30	KYNMOBI 30MG x 30
63402-0088-10	KYNMOBI TITRATION KIT x 10
63402-0301-01	LONHALA MAGNAIR REFILL 25MCG/ML x 60 (VIAL)
63402-0201-00	LONHALA MAGNAIR STARTER 25MCG/ML x 60 (VIAL)